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Abstract
Objective: Congenital pulmonary adenomatoid malformations (CPAM) are increasingly 
diagnosed in recent years thanks to the expert hands and the technology of ultrasonography 
used in antenatal diagnosis. The purpose was to examine a series of cases referred to our fetal-
maternal tertiary center for lung disease and to present the natural course, treatment and 
outcome of antenatally diagnosed cystic lung disease.
Material and Methods: We proposed a retrospective study (October 2003 to September 2016) 
in a single center. Prenatal and postnatal data of fetus, with suspected CPAM, where analyzed.
Results: We studied 34 cases. One child was excluded post-natally because at birth diagnosis of 
esophageal duplication was made. Mean gestational age at the diagnosis was 22 weeks (range 
21 to 28). Thoracoamniotic shunting was performed in 9 cases. In 8 cases, it was an intra-cystic 
drain and in 1 case, a pleuroamniotic drain. Mean gestational age for drainage was 25 weeks 
(range 22 to 28). Mean gestational age at delivery was 38 weeks. All patients underwent postnatal 
radiological assessment. Anatomical surgical resection was performed in all cases: immediately 
at birth in 7 symptomatic cases, in the first year of life for 1 case that became symptomatic and 
1 patient died immediately at birth due to severe respiratory distress.
Conclusion: Antenatally diagnosed CPAM have an excellent prognosis. We propose invasive 
prenatal thoracoamniotic shunting in rare cases with unequivocal fetal compromise (i.e., 
polydramnios and hydrops).
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Introduction
Congenital lung malformations include a spectrum of rare but 
clinically significant developmental abnormalities, including 
congenital pulmonary adenomatoid malformations (CPAM), 
bronchopulmonary sequestrations (BPS), bronchogenic cysts 
and congenital lobar emphysema. Many theories relating 
to the specific etiology of each of these anomalies have 
been proposed; nevertheless, it is generally agreed that they 
collectively result from perturbations in lung and airway 
embryogenesis. Moreover, these clinical entities as well as 
congenital high airway obstruction syndrome (CHAOS) are 
likely to have their origin in prenatal airway obstruction, 
differing only in the gestational age at which obstruction 
occurs. Antenatal diagnosis of lung malformations increased 
in recent years with the widespread use of antenatal ultrasound 
and improved technology [1-4].
CPAM is the most common lung lesion disease. The incidence 
of CPAM has been estimated to range from 1 in 25,000 to 
1 in 35,000 pregnancies. During pregnancy presentation of 
CPAMs range from fetal hydrops, mediastinal shift to complete 
in utero regression [5,6]. Postnatal presentation varies from 
severe respiratory distress to complete lack of symptoms. 
However, CPAM may not remain asymptomatic throughout 
life with complications including pneumonia, hemoptysis, 
pneumothorax, hemothorax and rarely malignancies 
potentially developing [1,7,8].
Although fetal therapies such as thoracoamniotic shunting 
can be applied to congenital cyst adenomatoid malformations 
of the lung diagnosed in utero, there is no clear consensus 
regarding their indications [9,10]. Our purpose was to evaluate 
a management policy in which aggressive fetal therapy was 
restricted to those cases complicated by major polydramnios 
or hydrops. All other cases were managed conservatively. 
We reviewed a consecutive series of prenatal management of 
CPAM to our neighboring tertiary referral center. 
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Materials and Methods 
We performed a retrospective study population (October 
2003 to September 2016). We included a series of consecutive 
patients referred to our tertiary center of fetal medicine, for 
fetal lung malformations detected at routine ultrasound. 
CPAM was diagnosed between 21 and 28 gestational weeks 
(medium: 22GW) (Table 1). For clinical management, the 
more recent classification into either micro- or macrocystic 
appearance on ultrasound is more relevant. Macrocystic 
(Stocker type I) lesions contain at least one cyst >5 mm, 
whereas microcystic (Stocker type III) lesions show no cyst 
and appear echogenic. Microcystic lesions tends to regress 
spontaneously after a growth peak at approximatively 26-28 
week’s gestation, but macrocystic lesions generally do not 
regress, as fluid accumulates in the cyst. 
To evaluate the size of the lesion, we calculated the percentage 
of the overall pulmonary area appearing pathological at 
ultrasound: less than 50% when it was unilateral, 50% with 
no normal lung on the CPAM side and no mediastinal shift. 
When mediastinal shift was observed the size was graded 
as more than 50% of the thorax.  We also considered the 
CPAM volume ratio (CVR) calculated from the size of the 
lesion and head circumference (HC): (lengh x height x width 
x 0.52)/HC. A CVR more than 1.6 is predictive of 80% risk of 
hydrops. Very large lesions carry a significant risk of causing 
both pulmonary hypoplasia due to compression of lung tissue 
and fetal hydrops, probably due to impaired cardiac function 
as a result of mediastinal shift and compression of lung tissue 
and fetal hydrops, probably due to impaired cardiac function 
as a result of mediastinal shift and compression of the vena 
cava or cardiac tamponade. 
Fetal thoracoamniotic shunt was offered in the case of 
macrocystic lesions with fetal hydrops or signs of evolving 
hydrops such as ascites, lesions that were either very large 
(CVR>1.6) or rapidly increasing in size that were associated 
with polyhydramnios. In the absence of any of these findings, 
fetuses were followed prospectively with serial ultrasound 
examinations. We obtained informed consent from the patient 
before any procedure.
Case No. Prenatal Diagnosis(CCAM) Gestational age




1 Type I 21 w <50% no <1.6 Yes
2 Type II 22 w <50% yes <1.6 No
3 Type I 22 w >50% yes >1.6 Yes
4 Type II 26 w >50% no <1.6 No
5 Type I 22 w >50% yes >1.6 No
6 Type III 25 w <50% yes <1.6 No
7 Type III 22 w >50% no <1.6 No
8 Type III 23 w <50% no <1.6 No
9 Type I 25 w <50% no <1.6 Yes
10 Type II 22 w <50% yes <1.6 No
11 Type II 24 w >50% yes >1.6 No
12 Type I 23 w >50% no <1.6 No
13 Type II 22 w <50% yes <1.6 No
14 Type I 23 w <50% no <1.6 No
15 Type II 23 w >50% no <1.6 No
16 Type III 23 w <50% yes <1.6 No
17 Type II 26 w >50% yes >1.6 Yes
18 Type III 22 w >50% yes >1.6 No
19 Type II 23 w <50% no <1.6 No
20 Type II 23 w <50% yes <1.6 No
21 Type II 26 w <50% no <1.6 No
22 Type III 22 w <50% no <1.6 No
23 Type I 22 w >50% no <1.6 No
24 Type I 25 w <50% no <1.6 No
25 Type III 24 w >50% yes >1.6 No
26 Type I 22 w <50% no <1.6 No
27 Type III 21 w <50% no <1.6 No
28 Type III 22 w >50% yes >1.6 No
29 Type I 21 w >50% yes <1.6 Yes
30 Type III 22 w >50% yes >1.6 No
31 Type III 25 w >50% yes <1.6 No
32 Type III 22 w >50% no <1.6 No
33 Type I 22 w <50% no <1.6 No
Table 1. Classification of our series of patients.
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Fetal intervention
We offered thoracentesis or placement of a thoracoamniotic 
shunt when hydrops developed prior to 32 weeks. This 
procedure resulted in resolution of both mediastinal shift 
and hydrops until successful delivery at 37-38 gestational 
weeks.  However, it was important to note that despite 
successful prenatal cyst decompression, these infants had 
significant pulmonary hypoplasia and mass effect at birth and 
potential side-effects due to fetal intervention are induction 
of premature labor or rupture of the membranes. 
All the uncomplicated cases were treated conservatively. 
Fetal karyotype was analysed in all cases. Fetal follow-up 
was monitored with serial prenatal ultrasonography every 1 
to 2 weeks (Figure 1).
Fetal shunt technique
In fetal shunt the drainage was inserted through the mother’s 
abdomen and uterus under echographic control. 
The procedure was performed in the hospital. The mother 
was hospitalized the day before, blood examination and 
anesthesiologist control was made. The day of the procedure 
the mother was fasting, and medicaments were done (Atarax 
and Imidazolam). Under ultrasonographic control and local 
anesthesia percutaneous thoracoamniotic drainage was 
inserted. We used a metal cannula that was introduced into 
the amniotic cavity, through the fetal chest wall into the 
largest cyst. A double-pigtail catheter (Rocked KCH Fetal 
Bladder Catheter, London) was inserted through the cannula, 
with one end in the cyst and the other in the amniotic cavity. 
The placenta was never traversed. 
Two intramuscular doses of betamethasone were given for 
fetal lung maturation if shunting took place between 24 and 
34 weeks’ gestation or subsequently at viability if shunts 
had been placed at <24 weeks’ gestation. Fetuses were never 
paralyzed for the procedure.
The mother was discharged the day after previous clinical 
and ecographic examination and was controlled weekly. 
Cesarean sections were not routinely performed. All 
women delivered in our tertiary centre, with neonatalology 
personnel in attendance. To avoid development of neonatal 
pneumothoraces, shunt were clamped immediately upon 
delivery.
Neonatal diagnosis of the mass included chest x-ray and 
when necessary, computed tomography. Depending of the 
conditions of the neonate, surgery was performed either 
as an emergency procedure or in the first year of life. 
Contraindications for prenatal drainage include: chromosomal 
abnormality, multiple gestation, associated malformations 
and the presence of other maternal medical or psychosocial 
risk factors [9-11].
Results
The mean gestational age at the diagnosis was 22 weeks 
(range 21 to 28). We classified fetuses according to the 
Stoker’classification: 11 type I, 11 type II and 12 type III. 
The malformation was bilateral in one case.
Of 34 cases, we considered 2 different groups: Group A 
(no prenatal drainage) and Group B (prenatal drainage). 
Thoracoamniotic shunting was performed in 10 cases, at 
the mean gestational age of 25 weeks (range 22 to 28). In 
9 cases it was a cystoamniotic drain but in 1 case it was a 
pleuroamniotic drain. In all patients, the size of the lesions 
decreased substantially.
In the postnatal course, one case of supposed type I CPAM 
was finally diagnosed as having esophageal duplication 
and was excluded. Two cases were diagnosed as having a 
Figure 1. Management for prenatally diagnosed CPAMs.
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pulmonary sequestration and one case a hybrid CPAM with 
a sequestration. 
Of the 33 cases in which the diagnosis of CPAM was 
confirmed post-natally, 9 were complicated by fetal hydrops 
and major polydramnios. The cyst occupied 50% or >50% of 
the thorax in 16 cases 48% (7 in the group B 43%) and <50% 
in 17 cases 52% (2 in Group B 11%), mediastinal shift was 
present in 16 cases 48% (4 in Group B 25%) and premature 
rupture of the membranes was present in 5 cases 15% 
(2 in Group B 40%). The mean gestational age (Group A and 
B) at delivery was 38 weeks (range 25 to 39 weeks).
The cesarean was performed in 11/33 cases at mean 
gestational age of 39 w (range 25 to 41) (Table 2). There are 
only 4 cesarean sections among the 9 drained cases. In Group 
B, respiratory distress at birth required respiratory support in 
all cases. One patient died. Associated anomalies were found 
in 2 cases such as pectus excavatum in one case and heart 
failure in the other case (Table 3).
All children (Group A and Group B) had a postnatal chest 
x-ray. Surgical treatment was performed in 7 cases in the 
neonatal period and in 1 case in the first year of life for Group 
B but in Group A we performed surgical treatment in the 
neonatal period in 2 cases and in 18 cases in first year of life 
respectively died at birth 5 patients, 4 in Group A and 1 in 
Group B, for respiratory distress.
In one bilateral case (Group B) we performed partial atypical 
resections in three different surgical times. Histopathology 
revealed isolated CPAM in 30, sequestration in 2 cases 
and hybrid lesion CPAM type II + sequestration in 1 case. 
The mean clinical and radiological follow-up was 5 years 
(between 2 months and 8 years).
Discussion
Antenatal diagnosis of congenital lung malformations has 
increased in the last decade with rapid advances in imaging 
technology and increasing use of fetal ultrasonography. The 
incidence seems to be increasing reporting 1 in 10,000 from 
Western Australia and 1 in 16,000 from Hong Kong. Probably 
this is correlated with the increasing antenatal ultrasound 
screening and improvement in ultrasound technology 
[3]. Differential antenatal diagnosis of congenital lung 
malformations includes CPAM, sequestration, bronchogenic 
cyst and congenital lobar emphysema. In our series, only 3 
children were wrongly diagnosed with CPAM on antenatal 
ultrasound while it was esophageal duplication in 1 case 
and bronco-pulmonary sequestration in 2 cases.  Once the 
diagnosis of CPAM is suspected, the child could be referred 
to a tertiary fetus-maternal center where further imaging 
can be accurately performed and prenatal counseling can be 
delivered.
The volume of the CPAM is measured and compared to the 
fetal head circumference. This ratio is known as the CPAM 
volume ratio (CVR). A CVR of 1.6 indicates a fetus at 
increased risk for the development of fetal hydrops. The need 
for shunting is determined not alone by CVR but also by fetal 
and maternal clinical conditions [12,13].
The basis for considering decompression of cysts in utero is 
the hypothesis that compression by CPAM is responsible of 
pulmonary hypoplasia and hydrops. Early hydrops clearly 
appears as the most important prognostic element. It is thought 
to be secondary to the extreme mediastinal shift caused by 
the CPAM, resulting in vena cava and cardiac compression. 






Drain Delivery Respiratory Distress Diagnosis Surgery
Associated 
Malformations
N° 1 Type 1 22 w 38 w Yes CCAM type 1 (LIR) 5 Days No
 N° 2 Type 1 21 w 39+6 w Yes CCAM type 1 (bilateral) 2 Days, 3 Months, 5 Years No
N° 3 Type 3 30+5 w 34 w Yes BPS 1 Day Heart Failure 
N° 4 Type 1 28 w 28 w Yes CCAM type 1 (LIR) 2 Days No
N° 5 Type 1 27 w 34+5 w Yes CCAM type 1 (LIL) 3 Days No
N° 6 Type 3 28 w 39+4 w Yes CCAM+BPS 9 Months No
N° 7 Type 2 23 w 38 w Yes CCAM type 2 (LSR) 1 Day No
N° 8 Type 1 25 w 38+6 w Yes CCAM type 1 - -
N° 9 Type 3 24 w 38+2 w Yes Death - -
Table 3. Classification of patients treated shunting antenatally.
Variables Group A Group B
Number of patients 24 9
M/F 11/13 6/4
Hybrid lesion (CCAM+BPS) 2 1
Cesarian delivery 7 4
Mean gestational age at delivery 38 w 38 w
Death 4 1
Table 2. Characteristics of our series of patient: Group A (patient treat conservately) Group B (patient drainated antenatally).
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congenital diaphragmatic hernia. Also polyhydramnios is 
frequently correlated with CPAM because fetal swallowing 
decreased due to esophageal compression by the mass. 
Another complication of space-occupying thoracic masses 
would be pulmonary hypoplasia secondary to compression 
of the remaining tissue [12-15]. Originally, it was suggested 
that, because of the dismal prognosis for hydropic fetuses 
with large cystic lung lesions, open fetal surgical resection 
should be offered. Subsequently, it has become clear that 
these fetuses can be successfully treated with the much less 
invasive approach for thoracoamniotic shunting. A recent 
systematic review showed an improved survival rate of 62% 
(15/24) in treated hydropic fetuses Vs 3% (1/33) in those 
untreated (OR, 19.28; 95% CI, 3.7-101) [16]. 
The role of fetal thoracoamiotic shunt is still controversial for 
several reasonscand is difficult to define on the base of the 
literature. Firstly, it may be difficult to predict the evolution 
of a macrocystic lung lesion (either in increase or decrease in 
size) and the sequence or timing of development of hydrops. 
Secondly, there are no randomized studies comparing 
treatment vs non-treatment in non-hydropic fetuses. Shunting 
is usually offered only in more severe cases, i.e., those with 
polyhydramnios, large lesions or severe mediastinal shift, 
whereas milder cases usually are not treated. 
In our center we consider invasive prenatal treatment only 
in case of unequivocal fetal compromise. We have not 
performed this procedure for CPAM type III, in which the 
only therapeutic treatment options were either delivery 
or open fetal surgery. Although cases eligible for fetal 
intervention should be carefully selected for the potential 
risk that this kind of procedure have (i.e., premature labor or 
premature rupture of membrane) [15-17]. Few studies have 
reported on macrocystic lung lesions specifically. Microcystic 
and macrocystic lesions seem to differ significantly in their 
growth patterns during pregnancy and in their prognosis. 
Whereas a decrease in size during the third trimester has 
been reported in combined groups of macro- and microcystic 
CPAMs, it has been suggested that macrocystic lesions may 
have a tendancy to invrease in size [18,19]. 
In recent literature, there is a limited experience of 
percutaneous laser ablation to treat multicystic lesions. 
Although tumor size decreased, the hydrops worsened and 
fetal death occurred [20]. Moreover other study in Korean 
population found that percutaneous injection of OK-432, a 
sclerosing agent, is also a good choice to treat these fetuses 
[21].
In our experience, shunting appeared useful in several cases. 
The advantages and potential complications of invasive 
management should be carefully weighed with regard to 
gestational age and the risk of premature labor. Perinatal 
management has much to gain from the precise prenatal 
diagnosis of CPAM, which allows for in utero therapy, for 
emergency surgery after delivery, and for appropriate follow 
up of less severe cases.
We treated symptomatic CPAMs in the first year of life with 
a good outcome. Asymptomatic CPAMs were observed 
and treated when they became symptomatic. We have not 
so long follow-up range 1 month to 8 years and we have no 
complications. The limitations of our study are that the data 
were retrospective and observational. Only shunted cases 
were evaluated and there was no control group, although we 
suggest that observing a control group of hydropic fetuses 
would be unethical. In the literature creasing evidence of 
complications of CPAMs including rapid expansion of 
CPAM during life and also Nars et al. from Toronto recently 
reported 4% incidence of pleuro-pulmonary blastoma in 
asymptomatic lung lesion non-treated. Rabdomiosarcoma 
have also been found to originate from CPAM.
Conclusion
We agree with recent literature that thoracoamniotic 
shunting should be offered for all hydropic fetuses with 
large macrocystic lung lesions and we suggest that it should 
be considered also for non-hydropic fetuses if the predicted 
risk of developing hydrops is high. Specifically, this includes 
fetuses with very large lung lesions that increase in size 
rapidly or are associated with polyhydramnios. We suggest 
that fetuses with large macrocystic lung lesions should be 
referred to a regional fetal medicine center for thorough 
evaluation and fetal intervention as appropriate to limit the 
risks linked to inexperienced surgeons. In our experience, a 
very good fetal outcome with a low complication rate can be 
achieved only in expert hands.
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